A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Clinical trial NCT04035486 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04035486
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-02
- Primary completion
- 2023-04-03
- Enrollment
- 587
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.